Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:		
that is important for the re		lab data, to support th	<ul> <li>Attach any additional documentatione authorization request). Information</li> </ul>	
			☐ URGE	NT
MEMBER INFORMATION	ON			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:		1		
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE	ID NUMBER:			
MALE FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERGIES:	
DISCLOSURE AUTHOR FOLLOWING LINK: PRI	PATIENT OR THE PRESC IZATION FORM WITH TH METHERAPEUTICS.COM ED REPRESENTATIVE (II	IIS REQUEST WHICI M/NOPP	I CAN BE FOUND AT THE	
	ENTATIVE'S PHONE NU			
PRESCRIBER INFORM	IATION			
LAST NAME:	ATION	FIRST NAME:		
PRESCRIBER SPECIA	I TV·	EMAII ADDRE	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONTACT PERSON:		
	ICAL DISPENSING INFO	RMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY	RENEWAL IF		HERAPY INITIATED:	
DURATION OF THERA	PY (SPECIFIC DATES):			
Continued on next page				

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.15.25 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	AME:			
	OTHER MEDICATIONS FOR THIS	CONDITION?			
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Type II diabetes for blood glucose co ☐ Heart Failure ☐ Type II diabetes with established car additional cardiovascular risk ☐ Chronic kidney disease					
Other diagnosis:	ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
Is patient going to be using drug	in a clinical trial? 🗌 Yes 🔲 No				
Patient is required to use the authorized generic dapagliflozin.  Does patient have an absolute contraindication to dapagliflozin?   Yes No Please submit documentation.  For patient with Type II Diabetes only, answer the following:  Is the patient's estimated glomerular filtration rate (GFR) below 25 mL/min/1.73 m2?*   Yes No *Please provide documentation.					
Is the patient on dialysis? □ Yes	□ No				
Is the patient already taking the requested medication? □ Yes □ No					
Was the patient's hemoglobin A1C (HbA1c) 7.0% or greater prior to therapy (HbA1c must be taken within the past 6 months if the patient has not been on this treatment previously)?* □ Yes □ No *Copy of HbA1c level required.					
Is the patient currently on metform	min?* □ Yes □ No				
Does the patient had an inadequate response or intolerance to metform?   Yes  No  *Please provide documentation					
Does the patient have at least one of the following contraindication to metformin? ☐ Yes ☐ No (Please Check one)					



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
□ Advanced liver disease with cirrhosis, portal hypertension, ascites, and/or hepatic encephalopathy
For patient with Type II diabetes with established cardiovascular disease and/or risks, answer the following:
Is the patient 40 years of age or older? □ Yes □ No
Does patient have Type II diabetes? □ Yes □ No
Does the patient have established cardiovascular disease as described as ischemic heart disease and/or cerebrovascular disease and/or peripheral arterial disease?   — Yes — No *Please provide documentation.
Is the patient a 55 year old(or older) male with dyslipidemia, hypertension and/or who smokes 5 or more cigarettes/day? ☐ Yes ☐ No
Is the patient a 60 year old(or older) female with dyslipidemia, hypertension and/or who smokes 5 or more cigarettes/day? □ Yes □ No
For patient with heart failure with or without diabetes, answer the following:
Has patient ever had NYHA class II, III, or IV symptoms of heart failure? ☐ Yes ☐ No *Please provide documentation
Does patient have ejection fraction of 49% or less? ☐ Yes ☐ No *Please provide documentation
Does patient have ejection fraction of greater than 49% □ Yes □ No *Please provide documentation.
Does patient's body mass index(BMI) equal less than 50kg/m²? ☐ Yes ☐ No <i>Please provide documentation.</i>
Does patient have a NT-proBNP greater than 300pg/ml? □ Yes □ No <i>Please provide documentation</i> .
For patients with A-fib, is the NT-proBNP greater than 600pg/ml?   Yes   No Please provide documentation.
IF NT-proBNP not available, does patient have a BNP >100pg/ml? □ Yes □ No <i>Please submit chart documentation.</i>
If NT-proBNP not available and patient has Atrial fibrillation (AF), does patient have a BNP >100pg/ml? □ Yes □ No <i>Please submit chart documentation</i>
Does the patient have structural heart disease such as one or more of the following:? □ Yes □ No  Please provide documentation from echocardiogram.  □ LA width >3.8cm □ LA length >5.0 cm □ LA area >20cm2 □ LA volume >55ml □ LA volume index >29ml/m2



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:	
Does patient have and eGFR less than 25ml/min/1.73m²? □ Yes □ No	
Has patient had a heart translplant or complex congenital heart disease? □ Yes □ No	
Does patient have severe <u>pulmonary disease</u> including severe COPD, requiring home oxygen therapy for their COPD, chronic nebulizer therapy or chronic oral steroid therapy for treatment of their severe COPD?   Yes  No Please submit chart documentation.	
Does patient have severe <u>pulmonary disease</u> including WHO group 1 primary pulmonary hypertension?   Output  Does patient have severe <u>pulmonary disease</u> including WHO group 1 primary pulmonary hypertension?  Does patient have severe <u>pulmonary disease</u> including WHO group 1 primary pulmonary hypertension?	
Does patient have any other condition or diagnosis causing patient's heart failure symptoms such as?   Yes  No Please submit chart documentation.	1
<ul> <li>□ Anemia</li> <li>□ hypothyroidism</li> <li>□ Known infiltrative cardiomyopathy(e.g. amyloid sarcoid, lymphoma, endomyocardial fibrosis)</li> <li>□ Active myocarditis</li> <li>□ Constrictive pericarditis</li> <li>□ Cardiac tamponade</li> </ul>	
<ul> <li>□ Known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy</li> <li>□ Arrhythmogenic right ventricular cardiomyopathy/dysplasia</li> <li>□ Uncorrected primary valvular disease</li> </ul>	
For patients with chronic kidney disease with or without diabetes, answer the following:	
Has patient had chronic kidney disease for 3 or more months?   Yes   No *Please provide documentation.	
Does patient have and estimated GFR(eGFR) that equals between 20 - 45ml/min/1.73m² (inclusive) Yes □ No *Please provide documentation.	? □
Does patient have and estimated GFR(eGFR) greater than or equal to 45 to less than or equal to 9045ml/min/1.73m² with urinary albumin:creatinine ratio greater than or equal to 200mg/G or protein:creatinine ratio greater than or equal to 300mg/G?   Yes  No *Please provide documentation.	
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any othe information the physician feels is important to this review?	er
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all	



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: N	MEMBER'S FIRST NAME:		
ATTESTATION: I attest the information provided is	true and accurate to the best of my knowledge. I		
understand that the Health Plan, insurer, Medical Gr	roup or its designees may perform a routine audit and the accuracy of the information reported on this form.		
Prescriber Signature or Electronic I.D. Verification	on: Date:		
<b>CONFIDENTIALITY NOTICE:</b> The documents acco	mpanying this transmission contain confidential health		
	e intended recipient, you are hereby notified that any		
	eliance on the contents of these documents is strictly		
prohibited. If you have received this information in el			
FAX) and arrange for the return or destruction of the			
FAX THIS FORM TO: 800-424-7640			

FAX 1713 FURINI 1U: 800-424-7040

**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

